Zobrazeno 1 - 10
of 36
pro vyhledávání: '"B. D. YE"'
Autor:
J Seo, S Kim, S Song, S H Shin, S Park, S W Hong, S W Hwang, S H Park, D H Yang, J S Byeon, S J Myung, S K Yang, Y J Kim, B D Ye
Publikováno v:
Journal of Crohn's and Colitis. 17:i786-i789
Background The clinical impact of continuing or stopping 5-aminosalicylate (5-ASA) after escalating to treatment with an anti-tumour necrosis factor (TNF) agent in patients with inflammatory bowel disease (IBD) is currently unclear. We aimed to compa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::710551b2acbbca773a8796f488719c4b
https://doi.org/10.1093/ecco-jcc/jjac190.0789
https://doi.org/10.1093/ecco-jcc/jjac190.0789
Autor:
J Van Oostrom, S Anjie, M Braad, J Horrigan, N Karimi, B Adi, G Ganesh, S K Yang, J Lasa, C Broër, A de Kruif, P Olivera Sendra, B D Ye, R Banerjee, S Connor, C Siegel, L Peyrin-Biroulet, K Gecse, G D'Haens
Publikováno v:
Journal of Crohn's and Colitis. 17:i337-i339
Background For patients living with inflammatory bowel diseases (IBD), the ultimate treatment goal is “normal life”. However, no patient-reported outcome measurement (PROM) exists to measure the level of life normality in IBD. We previously asked
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e013f0f8b9e9b3b0255e6c3796416c79
https://doi.org/10.1093/ecco-jcc/jjac190.0315
https://doi.org/10.1093/ecco-jcc/jjac190.0315
Autor:
J Seo, M H Lee, H Hong, E H Oh, S W Hwang, S H Park, D H Yang, J S Byeon, S J Myung, S K Yang, K S Bae, B D Ye
Publikováno v:
Journal of Crohn's and Colitis. 17:i892-i894
Background Infliximab (IFX), a monoclonal antibody approved for treating Crohn’s disease (CD), is known to show differing drug clearances in patients according to several clinical factors. However, information on the population pharmacokinetics (PK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebc2c4f90cb8f771669a6c0d7df18e28
https://doi.org/10.1093/ecco-jcc/jjac190.0892
https://doi.org/10.1093/ecco-jcc/jjac190.0892
Autor:
H S Lee, Y Lee, J Baek, Y Kim, S Park, S Jung, K K Kim, S W Hwang, J L Lee, S H Park, S K Yang, B Han, K Song, Y S Yoon, B D Ye
Publikováno v:
Journal of Crohn's and Colitis. 17:i157-i158
Background We aimed to assess the gene expression profiles of uninflamed small bowels in patients with Crohn’s disease (CD) to identify its accompanying molecular alterations. Methods We performed RNA sequencing of the uninflamed small bowel tissue
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::011356d2ca6f2c3c309cf32c2033d4a7
https://doi.org/10.1093/ecco-jcc/jjac190.0121
https://doi.org/10.1093/ecco-jcc/jjac190.0121
Autor:
I Blumenstein, S Xuan, R Panaccione, F Baert, M Barreiro-de Acosta, B D Ye, J Klaff, R Vladea, G Levy, C T J Holweg, Y Sanchez Gonzalez, M C Dubinsky
Publikováno v:
Journal of Crohn's and Colitis. 17:i333-i334
Background Upadacitinib (UPA) demonstrated efficacy and safety as induction and maintenance therapy for ulcerative colitis (UC) in Phase 3 trials U-ACHIEVE (NCT02819635) and U-ACCOMPLISH (NCT03653026). This post-hoc analysis aims to characterise the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3687a83b9835d7eebd3c1ed419864e88
https://doi.org/10.1093/ecco-jcc/jjac190.0309
https://doi.org/10.1093/ecco-jcc/jjac190.0309
Publikováno v:
Journal of Crohn's and Colitis. 17:i651-i652
Background CT-P13 SC is the only subcutaneous (SC) formulation of infliximab (IFX) approved to treat Crohn’s disease (CD) or ulcerative colitis (UC). The primary CT-P13 SC study reported no increased risk of immunogenicity (anti-drug antibody [ADA]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8287cf9d71e99113101d05c8384d9376
https://doi.org/10.1093/ecco-jcc/jjac190.0654
https://doi.org/10.1093/ecco-jcc/jjac190.0654
Publikováno v:
Journal of Crohn's and Colitis. 17:i306-i306
Background Total proctocolectomy has been recommended for patients with ulcerative colitis (UC)-associated dysplasia due to the risk of its progression to colorectal cancer or metachronous recurrence. Recently, endoscopic resection has been considere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::413ec0ad95a45095f21c689bb7be4f97
https://doi.org/10.1093/ecco-jcc/jjac190.0273
https://doi.org/10.1093/ecco-jcc/jjac190.0273
Autor:
A Yoon, K Kim, K Oh, E S Kim, E H Kim, S Kim, J Y Jeong, M N Kweon, S W Hwang, S H Park, S J Myung, S K Yang, B D Ye
Publikováno v:
Journal of Crohn's and Colitis. 16:i615-i616
Background Gut microbial dysbiosis has been suggested to contribute to pathogenesis of inflammatory bowel disease (IBD). Vedolizumab (VDZ), an α4β7 integrin blocker, has been used as an effective agent for patients with IBD. However, effect of VDZ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf5a84c921c65d5629a217ab842fe48b
https://doi.org/10.1093/ecco-jcc/jjab232.843
https://doi.org/10.1093/ecco-jcc/jjab232.843
Autor:
K Kim, S W Hong, J H Park, S W Hwang, S H Park, D H Yang, J S Byeon, S J Myung, S K Yang, J H Yoo, S J Boo, E S Kim, J Lee, K O Kim, B D Ye
Publikováno v:
Journal of Crohn's and Colitis. 16:i503-i504
Background A clinical decision support tool (CDST) has been developed and validated for predicting outcomes of vedolizumab (VDZ) therapy for patients with Crohn’s disease (CD) and ulcerative colitis (UC), respectively. We aimed to validate each CDS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34cc6220f1da3dab1ee1f4fb99e0a0c3
https://doi.org/10.1093/ecco-jcc/jjab232.686
https://doi.org/10.1093/ecco-jcc/jjab232.686
Publikováno v:
Journal of Crohn's and Colitis. 16:i584-i584
Background In comparison with the general population, patients with Crohn’s disease (CD) are at higher risk of developing small bowel adenocarcinoma (SBA). However, with low prevalence of SBA, data regarding the impact of CD on survival are lacking
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccdf8ea2dca7d6ae60da0eb626285de3
https://doi.org/10.1093/ecco-jcc/jjab232.802
https://doi.org/10.1093/ecco-jcc/jjab232.802